National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "5 Categories of Scientific Evidence--Animal Data." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
172
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

SUMMARY

The guiding principle related to animal data is as follows: “Even in the absence of information on adverse events in humans, evidence of harm from animal studies is often indicative of potential harm to humans. This indication assumes greatest importance when the route of exposure is oral, the formulation tested is identical or highly similar to that consumed by humans in an ingredient, and more than one species shows the same or similar toxicity.”

The rationale and importance of this principle have been presented, and the following corollaries, along with their rationales and limitations:

  • In the absence of specific evidence that certain animal study findings are irrelevant to humans, animal evidence should be used to evaluate potential human risk.

  • A lack of observed or reported detrimental effects in an animal study is not evidence that a particular substance is “safe.”

  • Veterinary toxicology information may be useful when it corroborates concerns raised by other types of data. Independent of other types of data, evidence of harm in livestock and other veterinary toxicology information is appropriate to consider as a signal prompting an initial review of an ingredient. In addition, the veterinary toxicology literature is also useful for generating hypotheses in need of testing in well-established animal models.

  • When there is no detailed understanding of pharmacokinetics to make a comparison between animals or humans possible, it is appropriate to assume that the most sensitive experimental animal studies are relevant to human health.

  • Much of the animal study data available for dietary supplement ingredients will not have the characteristics of ideal studies, but these studies should nonetheless be considered if they suggest possible human health risk.

  • Animal studies that predict possible serious harm or death warrant more attention than those that predict mild, self-limiting effects in humans.

  • Certain chronic animal toxicity or adverse biological effects data should be considered as immediate cause for higher or moderate concern, regardless of the presence of high-quality human data suggesting no acute toxicity (see Category A in Table 5-1).

  • The default assumption for cancer is a linear low-dose extrapolation. Carcinogenicity findings, particularly those that are accompanied by evidence of genotoxicity and observed in animals at ingested amounts within 100× of expected human exposure, are of particular concern.

Page
172
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)